Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
KANJINTI vs DANYELZA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
KANJINTI (pertuzumab, trastuzumab, and hyaluronidase-zzxf) is a combination of two HER2/neu receptor antagonists. Pertuzumab and trastuzumab bind to distinct extracellular domains of HER2, inhibiting downstream signaling, antibody-dependent cell-mediated cytotoxicity, and ligand-independent receptor dimerization. Hyaluronidase enhances subcutaneous tissue permeability.
Disialoganglioside GD2-binding monoclonal antibody that induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity against GD2-positive tumor cells.
Adjuvant treatment of HER2-overexpressing breast cancer,Metastatic HER2-positive breast cancer (first-line in combination with chemotherapy),Neoadjuvant treatment of locally advanced or early stage HER2-positive breast cancer
Neuroblastoma: in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and retinoic acid for treatment of pediatric patients with high-risk neuroblastoma who have achieved at least a partial response to prior first-line multiagent, multimodality therapy.
4 mg/kg IV over 90 minutes, then 2 mg/kg IV over 30 minutes weekly; or 8 mg/kg IV over 90 minutes, then 6 mg/kg IV over 30–90 minutes every 3 weeks.
1.5 m Ci/kg (0.037 MBq/kg) intravenously over 30 minutes on days 1, 3, and 5 of each 28-day cycle.
Terminal elimination half-life: 28–38 days (mean ~32 days). Consistent with Ig G1 monoclonal antibody clearance; supports every-3-week dosing for sustained exposure
Terminal elimination half-life is approximately 29 days (range 25–35 days) at steady state, supporting a weekly dosing schedule for maintaining therapeutic concentrations.
Pertuzumab and trastuzumab are monoclonal antibodies degraded via catabolic pathways similar to endogenous Ig G, primarily through reticuloendothelial system; not metabolized by CYP450 enzymes. Hyaluronidase is degraded by hyaluronidases in tissues.
Metabolized via catabolic pathways into small peptides and amino acids; no major CYP450 involvement.
Primarily hepatic metabolism; renal elimination of intact drug is minimal (<1%). Biliary/fecal excretion accounts for the majority of elimination (>90%)
Renal elimination accounts for approximately 80% of the administered dose as unchanged drug; the remaining 20% is excreted via the biliary/fecal route.
Non-specific binding to plasma proteins is negligible; >99% of trastuzumab circulates unbound (free). No significant binding to albumin or alpha-1-acid glycoprotein
Approximately 99% bound to plasma proteins, primarily albumin and low-density lipoproteins.
Mean Vd: 2.9–4.5 L/kg (approximately 200–300 L for a 70 kg patient), indicating distribution into tissues including lymph and interstitial space
Volume of distribution is approximately 0.2 L/kg, indicating limited extravascular distribution and confinement primarily to the plasma compartment.
Not applicable for oral administration; only IV administration is approved. Bioavailability by IV route is 100%
Only available as intravenous formulation; bioavailability is 100% by definition for IV administration, with no oral or other route available.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Safety and efficacy not established in severe renal impairment (Cr Cl <30 m L/min) or hemodialysis.
No dose adjustment recommended for mild to moderate renal impairment. Severe renal impairment or end-stage renal disease: not studied, use with caution.
No dose adjustment recommended for Child-Pugh A or B. Safety and efficacy not established in Child-Pugh C; use only if benefit outweighs risk.
No dose adjustment recommended for mild to moderate hepatic impairment (Child-Pugh A or B). Severe hepatic impairment (Child-Pugh C): not studied, use with caution.
Weight-based dosing: Same as adult schedule (mg/kg). Safety and efficacy established for children ≥2 years with HER2-overexpressing tumors; dosing based on body weight. Maximum area under the curve similar to adults.
Safety and efficacy not established in pediatric patients.
No specific dose adjustment. Increased incidence of cardiac dysfunction in elderly; monitor left ventricular ejection fraction (LVEF) frequently. Dose modifications for toxicity same as adults.
No specific dose adjustment recommended; monitor for toxicity due to potential age-related renal or hepatic impairment.
WARNING: CARDIOTOXICITY. KANJINTI can cause subclinical and clinical cardiac failure manifesting as CHF, and decreased LVEF. Evaluate cardiac function before and during treatment. Discontinue for clinically significant decline.
WARNING: SERIOUS INFUSION-RELATED REACTIONS AND NEUROTOXICITY. Premedicate for infusion-related reactions. Monitor for and manage neurotoxicity (severe neuropathic pain, transverse myelitis, posterior reversible encephalopathy syndrome).
Cardiotoxicity (LVEF decline, heart failure),Infusion-related reactions (including anaphylaxis),Pulmonary toxicity (interstitial lung disease, pneumonitis),Embryo-fetal toxicity (oligohydramnios, fetal renal impairment),Exacerbation of chemotherapy-induced neutropenia
Infusion-related reactions (hypotension, urticaria, bronchospasm); neurotoxicity (severe pain, transverse myelitis, PRES); myelosuppression; capillary leak syndrome; infections; electrolyte abnormalities; fever; hypersensitivity reactions; interference with tumor response assessment.
Known hypersensitivity to pertuzumab, trastuzumab, hyaluronidase, or any component of KANJINTI
None known.
No known food interactions. Avoid grapefruit juice unless directed by healthcare provider.
No specific food interactions are established for DANYELZA. Maintain adequate hydration and nutrition as tolerated. Avoid grapefruit and grapefruit juice if taking concomitant medications that are CYP3A4 substrates, though DANYELZA itself is not metabolized by CYP450 enzymes.
KANJINTI (trastuzumab) is an Ig G1 monoclonal antibody that crosses the placenta. Human data indicate a high risk of oligohydramnios, fetal renal impairment, and fetal death when administered during the second and third trimesters. Exposure during organogenesis (first trimester) may also carry risks, but data are limited. Use is contraindicated in pregnancy.
Based on its mechanism of action (GD2-directed antibody), DANYELZA may cause fetal harm. There are no adequate human data. In animal studies, administration resulted in embryofetal toxicity including malformations and growth retardation. Advise females of reproductive potential of the potential risk to a fetus. Use effective contraception during treatment and for at least 2 months after the last dose.
Trastuzumab is excreted in human milk at low levels. The milk-to-plasma ratio is unknown. Due to the potential for adverse effects in the breastfeeding infant, advise women to discontinue breastfeeding during treatment and for 7 months after the last dose.
No data on presence in human milk, effects on breastfed infant, or effects on milk production. Because of the potential for serious adverse reactions, advise women not to breastfeed during treatment and for at least 2 months after the last dose.
No specific dose adjustment is recommended in pregnancy; however, use is contraindicated. Pharmacokinetic changes in pregnancy (increased plasma volume, altered renal clearance) may affect trastuzumab exposure, but no dose adjustment guidelines exist. Therapy should be discontinued if pregnancy occurs.
Dosing adjustments during pregnancy are not established. Use only if potential benefit justifies potential risk to the fetus. Consider delaying treatment until after delivery if feasible.
KANJINTI (trastuzumab-anns) is a biosimilar to trastuzumab. Administer as IV infusion; observe for infusion reactions. Do not mix with dextrose solutions. Confirm HER2 overexpression before use (IHC 3+ or FISH+). Monitor left ventricular ejection fraction (LVEF) at baseline and every 3 months. Contraindicated in patients with LVEF <50% or significant decline. Cardiotoxicity risk increases with anthracycline pre-treatment. Use with caution in pregnant women; may cause fetal harm.
DANYELZA (naxitamab) is a GD2-binding monoclonal antibody for relapsed/refractory high-risk neuroblastoma. Premedicate with antihistamines, acetaminophen, and corticosteroids to mitigate infusion-related reactions. Monitor for severe pain, which is a known adverse effect; may require opioid analgesics. Closely monitor for hypotension and bronchospasm during infusion. Administer in a setting equipped to manage anaphylaxis.
Take only under prescription from a doctor.,Report any chest pain, shortness of breath, or swelling of ankles immediately.,Avoid pregnancy while on treatment; use effective contraception during and for 7 months after last dose.,Do not breastfeed during treatment and for 7 months after last dose.,Regular heart function tests (echocardiogram or MUGA) will be performed.,You may experience flu-like symptoms (fever, chills) after infusion; these are usually manageable.
DANYELZA is given intravenously over several hours, typically on consecutive days.,You may experience severe pain during or after infusion; report it immediately.,Common side effects include fever, nausea, vomiting, and low blood pressure.,Serious allergic reactions can occur; inform your doctor if you develop hives, trouble breathing, or swelling.,Avoid driving or operating machinery if you feel dizzy or tired after treatment.,Notify your healthcare provider of all medications you are taking, including over-the-counter drugs and supplements.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about KANJINTI vs DANYELZA, answered by our medical review team.
KANJINTI is a Monoclonal Antibody Antineoplastic that works by KANJINTI (pertuzumab, trastuzumab, and hyaluronidase-zzxf) is a combination of two HER2/neu receptor antagonists. Pertuzumab and trastuzumab bind to distinct extracellular domains of HER2, inhibiting downstream signaling, antibody-dependent cell-mediated cytotoxicity, and ligand-independent receptor dimerization. Hyaluronidase enhances subcutaneous tissue permeability.. DANYELZA is a Monoclonal Antibody Antineoplastic that works by Disialoganglioside GD2-binding monoclonal antibody that induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity against GD2-positive tumor cells.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between KANJINTI and DANYELZA depend on the specific clinical indication. These are both Monoclonal Antibody Antineoplastic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of KANJINTI is: 4 mg/kg IV over 90 minutes, then 2 mg/kg IV over 30 minutes weekly; or 8 mg/kg IV over 90 minutes, then 6 mg/kg IV over 30–90 minutes every 3 weeks.. The standard adult dose of DANYELZA is: 1.5 m Ci/kg (0.037 MBq/kg) intravenously over 30 minutes on days 1, 3, and 5 of each 28-day cycle.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between KANJINTI and DANYELZA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. KANJINTI is classified as Category C. KANJINTI (trastuzumab) is an IgG1 monoclonal antibody that crosses the placenta. Human data indicate a high risk of oligohydramnios, fetal renal impairment, and fetal death when ad. DANYELZA is classified as Category C. Based on its mechanism of action (GD2-directed antibody), DANYELZA may cause fetal harm. There are no adequate human data. In animal studies, administration resulted in embryofetal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.